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Regulating the anticancer properties of
organometallic dendrimers using pyridylferrocene
entities: synthesis, cytotoxicity and DNA binding
studies†
Preshendren Govender,a Tina Riedel,b Paul J. Dysonb and Gregory S. Smith*a
A new series of eight ﬁrst- and second-generation heterometallic ferrocenyl-derived metal–arene metal-
lodendrimers, containing ruthenium(II)–p-cymene, ruthenium(II)–hexamethylbenzene, rhodium(III)–
cyclopentadienyl or iridium(III)–cyclopentadienyl moieties have been prepared. The metallodendrimers
were synthesized by ﬁrst reacting DAB-(NH2)n (where n = 4 or 8, DAB = diaminobutane) with salicylalde-
hyde, and then the Schiﬀ-base dendritic ligands were reacted in a one-pot reaction with the appropriate
[(η6-p-iPrC6H4Me)RuCl2]2, [(η6-C6Me6)RuCl2]2, [(η5-C5Me5)IrCl2]2 or [(η5-C5Me5)RhCl2]2 dimers, in the
presence of 4-pyridylferrocene. Heterometallic binuclear analogues were prepared as models of the
larger metallodendrimers. All complexes have been characterized using analytical and spectroscopic
methods. The cytotoxicity of the heterometallic metallodendrimers and their binuclear analogues were
evaluated against A2780 cisplatin-sensitive and A2780cisR cisplatin-resistant human ovarian cancer cell
lines and against a non-tumorigenic HEK-293 human embryonic kidney cell line. The second generation
Ru(II)-η6-C6Me6 metallodendrimer is the most cytotoxic and selective compound. DNA binding experi-
ments reveal that a possible mode-of-action of these compounds involves non-covalent interactions
with DNA.
Introduction
Research on the design of heterometallic complexes as poss-
ible anticancer agents has flourished.1–6 Due to its favourable
electronic properties and ease of functionalization,7–12 ferro-
cene has been incorporated in various biologically active
systems,9,13,14 in an eﬀort to achieve a synergistic eﬀect
between the metal centers.15–20 Furthermore, simple deriva-
tives of ferrocene display good activity in vitro, with inhibition
of tumors observed in vivo.21,22 In the search for new tamoxi-
fen-like drugs, Jaouen and co-workers23,24 prepared ferrocifens
from 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenylbut-
1-ene), which are highly active ferrocenyl-derivatives of the
purely organic breast cancer drug tamoxifen. The increase in
activity is attributed to the dual action of the organic drug and
the Fenton chemistry (i.e. formation of singlet oxygen) of the
Fe centre.25,26 Moreover, the stability of ferrocene in aqueous
and aerobic media, the facility with which a large variety of
derivatives may be prepared, and its favorable electrochemical
properties, has resulted in ferrocene becoming a promising
molecule for incorporating in biological applications.12 Fur-
thermore, certain ferrocene-containing compounds exhibit
cytotoxicities comparable to the benchmark anticancer drug,
cisplatin.
Due to the undesirable side-eﬀects displayed by platinum-
based anticancer drugs,27,28 researchers have turned their
attention to other metals.29,30 One such metal is ruthenium,
as ruthenium complexes tend to be less cytotoxic in compari-
son to platinum compounds,31 and two promising Ru(III) anti-
cancer agents are undergoing clinical trials.32–35 The activity of
the Ru(III) anticancer agents is thought to be brought about by
reduction of the compounds to a Ru(II) species in vivo,33 and
consequently there is a growing interest in the preparation and
biological evaluation of ruthenium(II)–arene complexes.36–42
Two anticancer agents are at the forefront of this promising
class of organometallic compounds, RAED-C [(η6-p-cym)Ru
(ethylene-diamine)Cl]PF6,
43,44 and RAPTA-C [(η6-p-cym)Ru
(1,3,5-triaza-7-phosphaadamantane)Cl2].
45,46 The former is a
cytotoxic compound that binds preferentially to DNA,47
whereas the latter is a non-cytotoxic antitumor
compound,46,48–51 that displays an antiangiogenic eﬀect52 and
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6dt00849f
aDepartment of Chemistry, University of Cape Town, Rondebosch, 7701, Cape Town,
South Africa. Fax: +27-21-6505195; E-mail: gregory.smith@uct.ac.za
bInstitut des Sciences et Ingénierie Chimique, Ecole Polytechnique Fédérale de
Lausanne (EPFL), CH-1015 Lausanne, Switzerland
This journal is © The Royal Society of Chemistry 2016 Dalton Trans., 2016, 45, 9529–9539 | 9529
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 5
/6
/2
01
9 
7:
59
:3
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View Issue
binds preferentially to histone proteins.47,49 In addition, a host
of Rh(III)–Cp* and Ir(III)–Cp* (where Cp* = cyclopentadienyl)
derivatives have previously demonstrated pharmacological
properties,53–58 which promote further study of these
compounds.
The concept of combining organometallic complexes with
compounds of known therapeutic value is a growing area of
research, and coupled with the notion of multinuclearity that
can result in enhanced therapeutic activity,19,59–71 the combi-
nation is an attractive drug-design strategy. Moreover, one way
of introducing the notion of multinuclearity is to conjugate
therapeutic agents onto dendritic scaﬀolds,59,72–77 that could
potentially exploit the enhanced permeability and retention
(EPR) eﬀect.78–80
Recently, we reported tetranuclear and octanuclear N,O-
and N,N-ruthenium–arene metallodendrimers, with ferrocene
moieties functionalized on the periphery of the dendritic
scaﬀold. The majority of the compounds eﬃciently inhibit the
growth of both A2780 cisplatin-sensitive and A2780cisR cispla-
tin-resistant human ovarian cancer cells (i.e. IC50 < 5 μM).81 In
addition, these complexes displayed no cross-resistance to cis-
platin, with the metallodendrimers having a better activity
compared to their mononuclear complexes.
On the basis of the above observed results we hypothesized
that preparing ferrocenyl-derived metal–arene metallodendri-
mers, where the ferrocenyl moiety is coordinated directly to
the metal center rather than on the periphery, may further
enhance the antiproliferative activity of the compounds. In
this study, we describe the synthesis of a series of bidentate
heterometallic ferrocenyl-derived dendrimers containing
ruthenium(II)–p-cymene, ruthenium(II)–HMB (where HMB =
hexamethylbenzene), rhodium(III)–Cp* or iridium(III)–Cp*
(where Cp* = cyclopentadienyl) moieties [1][PF6]4–[8]PF6]8 (see
Scheme 1). The cytotoxicity of the complexes was evaluated
against the A2780 and the A2780cisR human ovarian cancer
cell lines, as well as against the non-cancerous human embryo-
nic kidney (HEK-293) cell line. In order to investigate whether
the antiproliferative activity is size-dependent, binuclear
model analogues [9][PF6]–[12][PF6] were also prepared and
evaluated.
Results and discussion
Synthesis of ferrocenyl-derived heterometallic
metallodendrimers
Ferrocenyl-derived heterometallic metallodendrimers
[1][PF6]4–[8][PF6]8 were prepared from the dinuclear precursors
[(η6-p-iPrC6H4Me)RuCl2]2, [(η6-C6Me6)RuCl2]2, [(η5-C5Me5)
IrCl2]2 or [(η5-C5Me5)RhCl2]2 and 4-ferrocenylpyridine, in the
presence of Et3N, functionalized onto known first- and second-
generation salicylaldiminepoly(propyleneimine) dendritic
ligands (L1, L2)82 (Scheme 1). The metallodendrimers were iso-
lated in moderate yields as hexafluorophosphate salts via a
metathesis reaction. Compounds [1][PF6]4–[8][PF6]8 are non-
hygroscopic, air- and moisture-stable orange solids, and are
soluble in dimethylsulfoxide, acetonitrile or acetone.
Compared to non-ferrocenyl neutral derivatives previously
reported,74,83 the 1H NMR spectra of [1][PF6]4–[8][PF6]8 show a
general downfield shift in signals due the cationic nature of
the complexes. More specifically, the imine proton appears
slightly more downfield from ca. 7.9 ppm (in the neutral
complex)74,83 to ca. 8.2 ppm (in the cationic complex). The
shift in the imine proton, the general downfield shift of the
aromatic protons and the disappearance of the phenolic
proton for [1][PF6]4–[8][PF6]8 compared to the free ligands L1
and L2, suggests coordination to the metal ion via the imine
nitrogen and phenolic oxygen. The protons on the substituted
and un-substituted Cp rings (of the ferrocenylpyridine moiety)
are assigned to the broad singlet and two broad multiplets
appearing in the region between 4.0 and 5.0 ppm for [1][PF6]4–
[8][PF6]8. The aliphatic protons of the dendritic core and den-
dritic arms occur as broadened peaks, between 1.2 ppm and
3.0 ppm and at similar chemical shifts to those of the dendri-
Scheme 1 Synthesis of ferrocenyl-derived heterometallic metallodendrimers [1][PF6]4–[8][PF6]8.
Paper Dalton Transactions
9530 | Dalton Trans., 2016, 45, 9529–9539 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 5
/6
/2
01
9 
7:
59
:3
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
tic ligands L1 and L2. All metallodendrimers [1][PF6]4–[8][PF6]8
show a loss of two-fold symmetry around the metal center
upon coordination of the N,O-dendritic ligand. Evidence for
this is provided by the presence of two sets of signals (one of
the signals is masked by the singlet observed for the un-substi-
tuted Cp ring) for the –CH2– group adjacent to the imine nitro-
gen, due to the diastereotopic nature of these protons induced
by the chiral metal center. As a result, the methyl protons of
the isopropyl group, on the arene ring, of the Ru–p-cymene
metallodendrimers [1][PF6]4 and [2][PF6]8 exhibit two broad
doublets in the range of 1.2–1.3 ppm. A broad singlet is
observed at 2.0 ppm (for [3][PF6]4 and [4][PF6]8) and at 1.6 ppm
(for [5][PF6]4 and [8][PF6]8) for the HMB and Cp* protons,
respectively.
The infrared spectra of metallodendrimers [1][PF6]4–
[8][PF6]8 display a shift for the (CvN)imine stretching vibration
from ca. 1630 cm−1 in the ligand (L1 or L2), to lower wavenum-
bers ca. 1611 cm−1, supporting coordination of the ligand to
the metal center via the imine nitrogen. This stretching
vibration also overlaps with the vibration observed for the
(CvN)pyridyl on the ferrocenylpyridine moiety. Inclusion of
solvent molecules resulted in elemental analysis data for
[1][PF6]4–[8][PF6]8 to within acceptable limits, and is similarly
observed with other previously reported metallodendri-
mers.72,81 High-resolution mass spectrometry data (run in the
positive-ion mode) is consistent with the proposed structures
of [1][PF6]4–[8][PF6]8, with a base peak observed corresponding
to a charged adduct.
Synthesis of ferrocenyl-derived heterometallic binuclear
complexes
Binuclear model complexes [9][PF6]–[12][PF6] were prepared to
evaluate whether there is a size dependency correlation
between the complexes prepared and their biological activity
(see below). Two equivalents of the monomeric ligand L3,84
were reacted with one equivalent of the particular metal-
dimer, in the presence of triethylamine, in a one-pot reaction
(Scheme 2). Subsequently, 4-ferrocenylpyridine was added to
the reaction mixture, which generated a cationic complex, and
the products were isolated as red or red-orange hexafluoro-
phosphate salts. The binuclear model complexes have similar
solubilities to their dendritic derivatives [1][PF6]4–[8][PF6]8.
Furthermore, the synthesis and purity of the heterometallic
model (analogues [9][PF6]–[12][PF6] were confirmed by
1H, 13C
{1H} NMR and infrared spectroscopy, elemental analysis and
mass spectrometry.
Biological activity
The antiproliferative activity of the cationic metallodendrimers
[1][PF6]4–[8][PF6]8 and the model compounds [9][PF6]–[12][PF6]
was established in vitro against the human ovarian cisplatin-
sensitive (A2780) and cisplatin-resistant (A2780cisR) cancer
cell lines and against the non-tumorigenic human embryonic
kidney (HEK-293) cell line (Table 1). The model complexes
[9][PF6]–[12][PF6] display modest activity in both cancer cell
lines and, notably, they are not cancer cell selective. However,
there is a considerable increase in cytotoxicity on moving to
the higher generation compounds, in particular, for the ferro-
cenyl-derived Ru–HMB metallodendrimers ([3][PF6]4 and
[4][PF6]8) and Rh–Cp* ([7][PF6]4 and [8][PF6]8). The first-gen-
eration metallodendrimers [3][PF6]4 (9.1 μM in A2780; 5.9 μM
in A2780cisR) and [7][PF6]4 (6.1 μM in A2780; 12.7 μM in
A2780cisR) and second-generation metallodendrimers
Scheme 2 Synthesis of ferrocenyl-derived heterometallic mononuclear complexes [9][PF6]–[12][PF6].
Table 1 IC50 values of [1][PF6]4–[12][PF6] against A2780 and A2780cisR
human ovarian cancer cells and non-tumorigenic HEK-293 human
embryonic kidney cells
Compound Ma nb
A2780
(IC50, μM)
A2780cisR
(IC50, μM)
HEK-293
(IC50, μM)
[1][PF6]4 Ru–Fe 8 107.2 ± 2.0 53.3 ± 0.1 138.3 ± 7.3
[2][PF6]8 Ru–Fe 16 26.6 ± 1.0 44.1 ± 1.7 20.3 ± 1.5
[3][PF6]4 Ru–Fe 8 9.1 ± 0.3 5.9 ± 0.01 11.6 ± 1.1
[4][PF6]8 Ru–Fe 16 4.7 ± 0.2 3.5 ± 0.2 5.7 ± 0.2
[5][PF6]4 Ir–Fe 8 46.4 ± 2.5 59.0 ± 0.6 35.9 ± 3.4
[6][PF6]8 Ir–Fe 16 11.7 ± 0.3 7.6 ± 1.3 13.6 ± 2.0
[7][PF6]4 Rh–Fe 8 6.1 ± 0.1 12.7 ± 1.0 19.0 ± 0.6
[8][PF6]8 Rh–Fe 16 10.7 ± 1.3 7.9 ± 0.4 9.4 ± 1.4
[9][PF6] Ru–Fe 2 29.2 ± 1.7 33.0 ± 2.4 28.7 ± 0.6
[10][PF6] Ru–Fe 2 19.7 ± 1.3 17.4 ± 1.0 16.1 ± 1.5
[11][PF6] Ir–Fe 2 39.6 ± 3.0 36.7 ± 0.2 31.1 ± 0.3
[12][PF6] Rh–Fe 2 59.0 ± 0.3 72.9 ± 0.3 65.5 ± 3.3
cisplatin Pt 1 1.5 ± 0.5 25 ± 5.0 10 ± 2.0
a Type of metal(s) present in the complex. bNumber of metals within
the complex.
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[4][PF6]8 (4.7 μM in A2780; 3.5 μM in A2780cisR), [6][PF6]8
(11.7 μM in A2780; 7.6 μM in A2780cisR) and [8][PF6]8 (10.7 μM
in A2780; 7.9 μM in A2780cisR) are the most active of the
series. With the exception of the p-cymene metallodendrimers
[1][PF6]4 and [2][PF6]8, and the first-generation Ir–Cp* metallo-
dendrimer [5][PF6]4, the metallodendrimers have similar cyto-
toxicites in both the sensitive and resistant cancer cell lines,
indicating that these compounds operate via a diﬀerent mech-
anism of action to that of cisplatin. Similar, IC50 values were
previously observed for the p-cymene derivatives (where ferro-
cene is functionalized onto the periphery of the metallodendri-
mer),81 were also observed for the p-cymene derivatives
[1][PF6]4 and [2][PF6]8, where the ferrocene moiety is directly
coordinated to the ruthenium center. The introduction of the
ferrocenyl moiety results in comparable cytotoxicities for the
Rh and Ir metallodendrimers reported here, to their neutral
RhCp*–Cl and IrCp*–Cl analogues reported previously.74
However, incorporation of pyridylferrocene group on [7][PF6]4
improves the activity of the compound compared to the first
generation neutral Rh–Cp*–Cl analogue (55 μM in A2780 and
126 μM in A2780cisR).74 Similarly, an improvement in activity
for the cationic ferrocenyl-derived Ru–HMB metallodendri-
mers [3][PF6]4 and [4][PF6]8 was observed compared to their
neutral Ru–HMB-Cl analogs (G1-Ru–HMB-Cl = 27 μM (A2780);
25 μM (A2780cisR); G2-Ru–HMB-Cl = 10 μM (A2780); 10 μM
(A2780cisR)) reported previously,83 with comparable activities
to their cationic Ru–HMB-PTA analogs (G1-Ru–HMB-PTA =
9 μM (A2780); 25 μM (A2780cisR); G2-Ru–HMB-PTA = 6 μM
(A2780); 12 μM (A2780cisR)).73 There is a correlation between
the size-dependency of the metallodendrimers and the cyto-
toxicity, with metallodendrimers [3][PF6]4 and [4][PF6]8 being
the only compounds to exhibit a significant degree of cancer
cell selectivity. A direct comparison between these systems
(ferrocene at the metal center) and the previously prepared
systems (ferrocene at the periphery)81 cannot be made as
diﬀerent in vitro biological studies were performed. However,
coordination of the pyridylferrocene moiety to the Ru center
aﬀords more cytotoxic compounds.
NMR stability study
Compound stability is important for biological applications
and, in the case of metal-based drugs, many compounds are
actually prodrugs and hence the identity of the compound that
reaches the cell can be important. Following uptake into the
cell, related ruthenium–arene-PTA complexes are activated via
aquation, generating the aqua species, a process that can
be monitored by NMR spectroscopy.85,86 Furthermore, to
investigate the influence of the bidentate chelating N,O-dendri-
tic ligands on the stability of the metallodendrimers in solu-
tion and to mimic the preparation of solutions prior to
biological assays, aqueous stability studies were performed
on selected complexes, in a mixture of DMSO-d6 : D2O
(50 : 50% v/v) at 37 °C, using 1H NMR spectroscopy. The HMB-
derivatives display the best in vitro activity, thus, the second-
generation metallodendrimer [4][PF6]8 and its closest binuc-
lear model analogue [10][PF6] were selected, and studies were
undertaken in DMSO-d6 : D2O (50 : 50% v/v) over 24 hours at
37 °C (Fig. 1).
The 1H NMR spectra of [4][PF6]8 and [10][PF6] (Fig. 1) show
that the compounds are stable in solution, with no side-pro-
ducts or the formation of the aqua-species observed over a
period of 24 hours. In addition, these data show that the com-
plexes are stable in deuterated dimethylsulfoxide, relevant
during the time period between preparation of the compound
stock solutions and dosing of the cancer cells in the assay.
Fig. 1 1H NMR spectra of [4][PF6]8 (top three spectra) and [10][PF6] (bottom 5 spectra) in DMSO-d6 : D2O (50 : 50% v/v) over 24 hours at 37 °C.
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UV-Vis study: interactions with a DNA model
DNA is a potential drug target for ruthenium–arene com-
pounds and is an important target in cancer therapy.87 Fur-
thermore, some of the most cytotoxic ruthenium drugs act as
DNA intercalators upon coordination to the suitable ancillary
ligand.40 In order to correlate the antiproliferative activity of
the metallodendrimers to possible interactions with DNA, a
UV-vis study was performed. The interactions of [4][PF6]8 (the
most active compound) and its model analogue [10][PF6] were
selected for the study and their interaction with Red Salmon
testes DNA monitored by UV-vis spectroscopy (Fig. 2).
The UV-vis spectra for both [4][PF6]8 and [10][PF6] display
hypochromic shifts (upon DNA addition) as the absorbance at
λmax = 320 nm (for [4][PF6]8) and λmax = 310 nm (for [10][PF6])
decrease, with no substantial red- or blue-shift observed for
λmax for both systems (Fig. 2). Similar hypochromic shifts were
reported with Cu(II), Co(II) and Ni(II) complexes upon addition
of increasing concentration of DNA,88 whereas norepinephrine
(DNA binding agent) displays a hyperchromic shift upon DNA
addition.89 A hyperchromic shift is usually associated with the
partial uncoiling of the DNA double helix, which exposes more
of the DNA base-pairs, which in turn results in the increase in
absorbance at λmax. However, hypochromic eﬀects are also
associated with non-covalent interactions between the complex
and DNA, such as intercalative binding,90 indicating that DNA
could be a relevant target for these compounds.
Conclusions
A series of bidentate heterometallic ferrocenyl-derived dendri-
mers containing ruthenium(II)–p-cymene, ruthenium(II)–HMB,
rhodium(III)–cyclopentadienyl or iridium(III)–cyclopentadienyl
moieties have been successfully synthesized and characterized.
Heterometallic model complexes were also prepared and
characterized (for comparison with the larger metallodendri-
mers). Antiproliferative studies performed on the metalloden-
drimers and the model binuclear complexes show that the
model complexes display limited activity, whereas the metallo-
dendrimers display higher cytotoxicities, particularly the
second-generation ferrocenyl-derived ruthenium(II)–hexa-
methylbenzene metallodendrimer, which displayed the best
activity of the series. The presence of ferrocene leads to more
cytotoxic compounds compared to previously reported non-
ferrocenyl derivatives. In addition, these metallodendrimers
displayed no cross-resistance to cisplatin and some are cancer
cell selective, being less cytotoxic to the non-tumorigenic cells
included in the study. Spectroscopic studies illustrate that
these systems are stable in solution and additional DNA
binding studies suggest that a possible mode-of-action of
these metallodendrimers (at least for the most active deriva-
tive) involves possible non-covalent interactions (illustrated by
UV-vis experiments) with the DNA.
Experimental
General details
All solvents and reagents were purchased from Sigma-Aldrich;
DAB-G2-PPI-(NH2)8 was purchased from SyMO-Chem and used
without further purification. Ruthenium trichloride trihydrate,
iridium trichloride trihydrate and rhodium trichloride trihy-
drate were obtained from Heraeus Limited. L1,82 L2,82 L3,84
[(η6-p-iPrC6H4Me)RuCl2]2,91 [(η6-C6Me6)RuCl2]2,92 [(η5-C5Me5)
IrCl2]2,
93 [(η5-C5Me5)RhCl2]2,93 and 4-ferrocenylpyridine
(4-FcPyr)16 were prepared according to literature procedures.
Infrared (IR) spectra determined in the solid state on a Perkin-
Elmer Spectrum 100 FT-IR spectrometer equipped with a
SMART iTR ATR unit. The intensity of stretching vibrations are
Fig. 2 UV-vis absorption spectra of 0.15 mM [10][PF6] (left) and 0.23 mM [4][PF6]8 (right) in 0.2 mM HEPES buﬀer, pH 6.3 at 37 °C, in H2O in the
absence and then in the presence of increasing concentration of Red Salmon testes DNA.
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marked as strong (s), medium (m) and weak (w). Nuclear mag-
netic resonance (NMR) spectra were recorded on a Varian
Mercury XR300 spectrometer (1H: 300.08 MHz; 13C{1H}:
75.46 MHz) or Bruker Biospin GmbH spectrometer (1H:
400.22 MHz; 13C{1H}: 100.65 MHz) at ambient temperature.
Chemical shifts δ in ppm indicate a downfield shift relative to
tetramethylsilane (TMS) and were referenced relative to the
signal of the solvent.94 Individual peaks are marked as singlet
(s), doublet (d), doublet-of-doublet (dd), triplet (t), or multiplet
(m). High-resolution electrospray ionization-mass spec-
trometry (HR-ESI-MS) was carried out on a Waters Synapt mass
spectrometer. Data were recorded in positive ion mode.
Elemental analysis (C, H, N) was carried out using a Thermo
Flash 1112 Series CHNS-O Analyzer. For certain metallodendri-
mers, the analyses are outside acceptable limits, which is
ascribed to the encapsulation of solvent molecules and/or
other inorganic salts by the dendritic compounds. UV-vis
absorption studies were carried out on a Cary UV-vis spectro-
photometer using a 1 cm path length quartz cuvette to carry
out the measurements.
Compound synthesis
General synthesis of cationic N,O-(η6-arene)-Ru(II)-ferroce-
nylpyridine metallodendrimers ([1][PF6]4–[4][PF6]8). Triethyl-
amine (0.038 mL, 0.263 mmol for [1][PF6]4; 0.036 mL,
0.258 mmol for [2][PF6]8; 0.035 mL, 0.254 mmol for [3][PF6]4;
0.037 mL, 0.265 mmol for [4][PF6]8) was added to a stirred sus-
pension of L1 (0.0476 g, 0.0649 mmol for [1][PF6]4; 0.0460 g,
0.0628 mmol for [3][PF6]4) or L2 (0.0514 g, 0.0320 mmol for
[2][PF6]8; 0.0528 g, 0.0329 mmol for [4][PF6]8) in a EtOH : DCM
(50 : 50, 30 mL) mixture. The resulting yellow-suspension
was stirred at room temperature for 0.5 hour. Next,
[(η6-p-iPrC6H4Me)RuCl2]2 (0.0815 g, 0.133 mmol for [1][PF6]4;
0.0794 g, 0.130 mmol for [2][PF6]8) or [(η6-C6Me6)RuCl2]2
(0.0870 g, 0.129 mmol for [3][PF6]4; 0.0901 g, 0.133 mmol for
[4][PF6]8) was added to the reaction mixture. The reaction
mixture was stirred overnight at room temperature, then, the
reaction mixture was filtered and the filtrate reduced to ca.
5 mL. This was followed by the addition 4-ferrocenylpyridine
(0.0692 g, 0.263 mmol for [1][PF6]4; 0.0678 g, 0.258 mmol for
[2][PF6]8; 0.0669 g, 0.254 mmol for [3][PF6]4; 0.0696 g,
0.265 mmol for [4][PF6]8) and the solution was stirred at RT for
2 hours and filtered. NH4PF6 (0.0429 g, 0.263 mmol for
[1][PF6]4; 0.0420 g, 0.258 mmol for [2][PF6]8; 0.0414 g,
0.254 mmol for [3][PF6]4; 0.0431 g, 0.264 mmol for [4][PF6]8)
was added to the filtrate at 0 °C and stirred for 4 hours. An
orange-red precipitate was observed. The solid was isolated by
filtration, washed with isopropanol and finally with Et2O. The
solid was dried in vacuo.
[DAB-G1-PPI-{(η
6-p-cymene)Ru((C7H5NO)-κ
2-N,O)-4-ferrocenylpyr-
idine)}4][PF6]4 ([1][PF6]4). Orange solid. Yield: 0.120 g, 57%.
IR (ATR): ν (cm−1) = 1611 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 0.96–1.21 & 1.24–1.32 (br m, 24H,
CH(CH3)2 p-cymene), 1.71–2.26 (overlapping m, 24H, NCH2CH2 core,
NCH2CH2 core, NCH2CH2CH2Nbranch, NCH2CH2CH2Nbranch),
2.51–3.11 (br m, 16H, CH3 p-cymene, CH(CH3)2 p-cymene), 3.96 (br
s, 20H, Cp–CHunsubst. ring), 4.32–4.64 (overlapping br m, 16H,
NCH2CH2CH2Nbranch, Cp–CH), 4.70–4.98 (m, 8H, Cp–CH),
5.54–5.76 (m, 8H, Arp-cymene), 5.81–6.03 (m, 8H, Arp-cymene),
6.27–6.41 (m, 4H, Ar), 6.87–7.02 (br m, 8H, 2 × Ar), 7.09–7.24
(m, 4H, Ar), 7.39–7.63 (m, 8H, Pyr), 8.11 (br s, 4H, CHimine),
8.39–8.55 (m, 8H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm) =
17.0, 21.5, 22.1 (CH3 p-cymene); 50.7, 66.4, 69.7, 70.2, 71.7 (CH2);
67.5, 71.6 (Cp–CH); 70.3 (Cp–CHunsubst. ring); 78.0 (CCp); 30.8,
83.1, 84.1, 84.5, 88.8 (CHp-cymene); 99.8, 119.9 (Cp-cymene); 115.0,
121.3, 135.0, 135.1 (CHAr); 120.0 (Cpyr); 121.7, 152.5 (CHpyr);
152.9, 164.9 (CAr); 165.9 (CHimine). Elemental analysis for
C140H160F24Fe4N10O4P4Ru4·2DCM (3424.2436): Found C, 49.86;
H, 4.47; N, 3.94%; calcd C, 49.81; H, 4.83; N, 4.09%. MS
(HR-ESI-TOF, m/z): 417.8664 [M − 4(4-FcPyr)]4+ (where M =
[1][PF6]4 − 4PF6).
[DAB-G2-PPI-{(η
6-p-cymene)Ru((C7H5NO)-κ
2-N,O)-4-ferrocenylpyr-
idine)}8][PF6]8 ([2][PF6]8). Orange solid. Yield: 0.1207 g, 56%.
IR (ATR): ν (cm−1) = 1612 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 1.02–1.20 & 1.23–1.35 (br m, 48H,
CH(CH3)2 p-cymene), 1.56–3.17 (overlapping m, 64H,
NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N1st branch,
NCH2CH2CH2N1st branch, NCH2CH2CH2N1st branch,
NCH2CH2CH2N2nd branch, NCH2CH2CH2N2nd branch), 2.87 (br m,
32H, CH3 p-cymene, CH(CH3)2 p-cymene), 3.96 (br s, 40H,
Cp–CHunsubst. ring), 4.44–4.70 (br m, 32H,
NCH2CH2CH2N2nd branch, Cp–CH), 4.78–4.98 (m, 16H, Cp–CH),
5.57–5.81 (m, 16H, Arp-cymene), 5.86–6.04 (m, 8H, Arp-cymene),
6.32–6.42 (m, 8H, Ar), 6.97–7.11 (br m, 16H, 2 × Ar), 7.16–7.27
(m, 8H, Ar), 7.43–7.61 (m, 16H, Pyr), 8.16 (br s, 8H, CHimine),
8.40–8.58 (m, 16H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm) =
17.0, 21.5, 22.1 (CH3 p-cymene); 49.0, 52.4, 66.6, 69.8 (CH2); 67.6,
71.7 (Cp–CH); 70.3 (Cp–CHunsubst. ring); 78.0 (CCp); 30.8, 83.2,
84.2, 84.6, 89.2 (CHp-cymene); 99.9, 120.0 (Cp-cymene); 115.0,
121.7, 135.0, 134.8, 135.1 (CHAr); 120.8 (Cpyr); 121.3, 152.2
(CHpyr); 153.5, 164.7 (CAr); 165.5 (CHimine). Elemental analysis
for C296H336F48Fe8N22O8P8Ru8·9DCM (7509.4676): Found C,
48.51; H, 4.67; N, 4.39%; calcd C, 48.78; H, 4.75; N, 4.10%. MS
(HR-ESI-TOF, m/z): 533.0239 [M − 3(4-FcPyr) + H]9+ (where M =
[2][PF6]8 − 8PF6).
[DAB-G1-PPI-{(η
6-HMB)Ru((C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine)}4][PF6]4 ([3][PF6]4). Orange solid. Yield: 0.0749 g, 35%.
IR (ATR): ν (cm−1) = 1610 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 1.27–1.55 (br m, 4H, NCH2CH2 core),
1.77–1.88 (m, 8H, NCH2CH2CH2Nbranch), 2.03 (br s, 72H, ArHMB),
2.38–2.71 (overlapping m, 12H, NCH2CH2 core,
NCH2CH2CH2Nbranch), 3.59–3.75 (br m, 8H,
NCH2CH2CH2Nbranch), 4.05 (br s, 20H, Cp–CHunsubst. ring),
4.53–4.62 (m, 8H, Cp–CH), 4.90–5.00 (m, 8H, Cp–CH), 6.51–6.62
(m, 4H, Ar), 6.84–6.96 (m, 4H, Ar), 7.06–7.23 (m, 4H, Ar),
7.28–7.42 (m, 4H, Ar), 7.66–7.80 (m, 8H, Pyr), 8.14 (br s, 4H,
CHimine), 8.45–8.63 (m, 8H, Pyr).
13C{1H} NMR ((CD3)2CO):
δ (ppm) = 14.7 (CH3 HMB); 25.4, 51.0, 66.9, 69.8, 70.2 (CH2); 67.5,
71.7 (Cp–CH); 70.3 (Cp–CHunsubst. ring); 78.0 (CCp); 94.2 (CHMB);
115.4, 123.3, 134.4, 134.6 (CHAr); 121.8 (Cpyr); 122.1, 151.4 (CHpyr);
153.2, 165.1 (CAr); 165.7 (CHimine). Elemental analysis for
C156H196N18F24Fe4O4P8Ru4·2IPOH (3486.7828): Found C, 53.54;
Paper Dalton Transactions
9534 | Dalton Trans., 2016, 45, 9529–9539 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 5
/6
/2
01
9 
7:
59
:3
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
H, 5.23; N, 4.49%; calcd C, 53.05; H, 5.55; N, 4.02%. MS
(HR-ESI-TOF, m/z): 428.1369 [M − (4-FcPyr) + 2H]6+ (where M =
[3][PF6]4 − 4PF6).
[DAB-G2-PPI-{(η
6-HMB)Ru((C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine)}8][PF6]8 ([4][PF6]8). Orange solid. Yield: 0.0764 g, 33%.
IR (ATR): ν (cm−1) = 1610 (s & br, imine & pyridine, CvN).
1H NMR ((CD3)2CO): δ (ppm) = 1.56–3.33 (overlapping m, 64H,
NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N1st branch,
NCH2CH2CH2N1st branch, NCH2CH2CH2N1st branch,
NCH2CH2CH2N2nd branch, NCH2CH2CH2N2nd branch), 2.00 (br s,
144H, ArHMB), 3.57–3.75 (br m, 16H, NCH2CH2CH2N2nd branch),
4.05 (br s, 40H, Cp–CHunsubst. ring), 4.52–4.61 (m, 16H, Cp–CH),
4.91–5.01 (m, 16H, Cp–CH), 6.50–6.61 (m, 8H, Ar), 6.80–6.97
(m, 8H, Ar), 7.13–7.22 (m, 8H, Ar), 7.27–7.40 (m, 8H, Ar),
7.68–7.78 (m, 16H, Pyr), 8.09 (br s, 8H, CHimine), 8.49–8.65 (m,
16H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm) = 14.7 (CH3 HMB);
21.9, 51.0, 51.9, 61.8, 69.8 (CH2); 67.5, 71.7 (Cp–CH); 70.3
(Cp–CHunsubst. ring); 78.4 (CCp); 94.2 (CCp*); 115.4, 123.4, 134.4,
134.5 (CHAr); 120.5 (Cpyr); 122.1, 151.4 (CHpyr); 152.8, 165.0
(CAr); 165.8 (CHimine). Elemental analysis for C296H336F48Fe8-
N22O8P8Ru8·3DCM (7224.2996): Found C, 52.20; H, 5.24; N,
4.49%; calcd C, 52.37; H, 5.22; N, 4.27%. MS (HR-ESI-TOF,
m/z): 562.0537 [M − 5(4-FcPyr)]8+ (where M = [4][PF6]8 − 8PF6).
General synthesis of cationic N,O-(η5-C5Me5)-M(III)-ferroce-
nylpyridine metallodendrimers (where M = Ir or Rh, [5][PF6]4–
[8][PF6]8). [5][PF6]4–[8][PF6]8 were obtained in an analogous
manner as [1][PF6]4–[4][PF6]8, using triethylamine (0.038 mL,
0.276 mmol for [5][PF6]4; 0.038 mL, 0.271 mmol for [6][PF6]8;
0.039 mL, 0.280 mmol for [7][PF6]4; 0.037 mL, 0.254 mmol for
[8][PF6]8), L1 (0.0513 g, 0.0681 mmol for [5][PF6]4; 0.0507 g,
0.0692 mmol for [7][PF6]4) or L2 (0.0541 g, 0.0337 mmol for
[6][PF6]8; 0.0508 g, 0.0316 mmol for [8][PF6]8), [(η5-C5Me5)
IrCl2]2 (0.109 g, 0.276 mmol for [5][PF6]4; 0.111 g, 0.135 mmol
for [6][PF6]8) or [(η5-C5Me5)RhCl2]2 (0.0876 g, 0.142 mmol for
[7][PF6]4; 0.0795 g, 0.128 mmol for [8][PF6]8), 4-ferrocenylpyri-
dine (0.0726 g, 0.276 mmol for [5][PF6]4; 0.0541 g,
0.0337 mmol for [6][PF6]8; 0.0737 g, 0.280 mmol for [7][PF6]4;
0.0670 g, 0.254 mmol for [8][PF6]8) and NH4PF6 (0.0450 g,
0.276 mmol for [5][PF6]4; 0.0442 g, 0.271 mmol for [6][PF6]8;
0.0457 g, 0.280 mmol for [7][PF6]4; 0.0415 g, 0.254 mmol for
[8][PF6]8).
[DAB-G1-PPI-{(η
5-C5Me5)Ir((C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine)}4][PF6]4 ([5][PF6]4). Orange solid. Yield: 0.151 g, 61%.
IR (ATR): ν (cm−1) = 1612 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 1.26–1.60 (overlapping m, 72H,
ArCp*, NCH2CH2 core, NCH2CH2CH2Nbranch), 2.23–2.66 (overlap-
ping m, 12H, NCH2CH2 core, NCH2CH2CH2Nbranch), 4.06 (br s,
20H, Cp–CHunsubst. ring), 4.15–4.39 (br m, 8H,
NCH2CH2CH2Nbranch), 4.51–4.67 (m, 8H, Cp–CH), 4.89–5.07
(m, 8H, Cp–CH), 6.52–6.67 (m, 4H, Ar), 6.98–7.09 (m, 4H, Ar),
7.21–7.33 (m, 4H, Ar), 7.38–7.52 (m, 4H, Ar), 7.69–7.88 (m, 8H,
Pyr), 8.13 (br s, 4H, CHimine), 8.58–9.02 (m, 8H, Pyr).
13C{1H}
NMR ((CD3)2CO): δ (ppm) = 7.76 (CH3 Cp*); 24.0, 49.8, 53.4,
63.9, 69.7, 71.7 (CH2); 67.7, 71.6 (Cp–CH); 70.4 (Cp–CHunsubst. ring);
77.9 (CCp); 94.2 (CCp*); 116.4, 122.7, 134.4, 135.0 (CHAr); 122.3
(Cpyr); 122.1, 150.3 (CHpyr); 153.8, 164.1 (CAr); 163.6 (CHimine).
Elemental analysis for C140H164F24Fe4Ir4N10O4P4·3DCM
(3877.808): Found C, 44.49; H, 4.45; N, 3.63%; calcd C, 44.29;
H, 4.42; N, 3.61%. MS (HR-ESI-TOF, m/z): 626.0876 [M + K]5+
(where M = [5][PF6]4 − 4PF6).
[DAB-G2-PPI-{(η
5-C5Me5)Ir((C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine)}8][PF6]8 ([6][PF6]8). Orange solid. Yield: 0.177 g, 70%.
IR (ATR): ν (cm−1) = 1613 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 1.32–3.08 (overlapping m, 64H,
NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N1st branch,
NCH2CH2CH2N1st branch, NCH2CH2CH2N1st branch,
NCH2CH2CH2N2nd branch, NCH2CH2CH2N2nd branch), 1.51 (br s,
120H, ArCp*), 4.05 (br s, 40H, Cp–CHunsubst. ring), 4.21–4.38 (br
m, 16H, NCH2CH2CH2N2nd branch), 4.52–4.66 (m, 16H, Cp–CH),
4.91–5.07 (m, 16H, Cp–CH), 6.48–6.66 (m, 8H, Ar), 6.97–7.10
(m, 8H, Ar), 7.25–7.31 (m, 8H, Ar), 7.33–7.40 (m, 8H, Ar),
7.66–7.88 (m, 16H, Pyr), 8.19 (br s, 8H, CHimine), 8.59–8.83 (m,
16H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm) = 7.8 (CH3 Cp*);
23.8, 49.9, 51.4, 63.7, 69.7 (CH2); 67.7, 71.9 (Cp–CH); 70.4
(Cp–CHunsubst. ring); 77.6 (CCp); 87.1 (CCp*); 116.4, 122.7, 134.5,
135.0 (CHAr); 122.3 (Cpyr); 122.1, 150.3 (CHpyr); 153.5, 163.9
(CAr); 163.5 (CHimine). Elemental analysis for C296H344F48Fe8Ir8-
N22O8P8·10DCM (8331.6636): Found C, 44.01; H, 4.00; N,
3.89%; calcd C, 44.11; H, 4.40; N, 3.70%. MS (HR-ESI-TOF, m/
z): 626.0886 [M − 5(4-FcPyr)]8+ (where M = [6][PF6]8 − 8PF6).
[DAB-G1-PPI-{(η
5-C5Me5)Rh((C7H5NO)-κ
2-N,O)-4-ferrocenylpyr-
idine)}4][PF6]4 ([7][PF6]4). Orange solid. Yield: 0.126 g, 56%.
IR (ATR): ν (cm−1) = 1611 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 1.24–1.73 (overlapping m, 72H,
ArCp*, NCH2CH2 core, NCH2CH2CH2Nbranch), 2.17–3.04 (overlap-
ping m, 12H, NCH2CH2 core, NCH2CH2CH2Nbranch), 4.06–4.24
(br m, 28H, Cp–CHunsubst. ring, NCH2CH2CH2Nbranch),
4.50–4.61 (m, 8H, Cp–CH), 4.91–5.00 (m, 8H, Cp–CH),
6.52–6.73 (m, 4H, Ar), 7.01–7.14 (m, 4H, Ar), 7.19–7.26 (m, 4H,
Ar), 7.31–7.48 (m, 4H, Ar), 7.67–7.86 (m, 8H, Pyr), 8.22 (br s,
4H, CHimine), 8.53–8.76 (m, 8H, Pyr).
13C{1H} NMR ((CD3)2CO):
δ (ppm) = 8.02 (CH3 Cp*); 24.5, 50.2, 60.9, 69.7, 71.7 (CH2);
67.6, 71.7 (Cp–CH); 70.3 (Cp–CHunsubst. ring); 78.3 (CCp); 95.1
(CCp*); 115.5, 123.3, 134.8, 135.0 (CHAr); 122.0 (Cpyr); 122.7,
150.6 (CHpyr); 153.2, 164.7 (CAr); 166.2 (CHimine). Elemental
analysis for C140H164F24Fe4N10O4P4Rh4·2DCM (3435.6352):
Found C, 49.46; H, 4.66; N, 3.88%; calcd C, 49.64; H, 4.93; N,
4.08%. MS (HR-ESI-TOF, m/z): 617.8252 [M − (4-FcPyr)]4+
(where M = [7][PF6]4 − 4PF6).
[DAB-G2-PPI-{(η
5-C5Me5)Rh((C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine)}8][PF6]8 ([8][PF6]8). Orange solid. Yield: 0.119 g, 56%. IR
(ATR): ν (cm−1) = 1611 (s & br, imine & pyridine, CvN). 1H NMR
((CD3)2CO): δ (ppm) = 1.25–3.41 (overlapping m, 64H,
NCH2CH2 core, NCH2CH2 core, NCH2CH2CH2N1st branch,
NCH2CH2CH2N1st branch, NCH2CH2CH2N1st branch,
NCH2CH2CH2N2nd branch, NCH2CH2CH2N2nd branch), 1.52 (br s,
120H, ArCp*), 3.97–4.33 (br m, 56H, Cp–CHunsubst. ring,
NCH2CH2CH2N2nd branch), 4.49–4.59 (m, 16H, Cp–CH),
4.90–4.98 (m, 16H, Cp–CH), 6.53–6.70 (m, 8H, Ar), 7.03–7.16
(m, 8H, Ar), 7.24–7.51 (br m, 16H, 2 × Ar), 7.69–7.94 (m, 16H,
Pyr), 8.25 (br s, 8H, CHimine), 8.53–8.68 (m, 16H, Pyr).
13C{1H}
NMR ((CD3)2CO): δ (ppm) = 7.79 (CH3 Cp*); 24.6, 50.1, 51.8,
Dalton Transactions Paper
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63.7, 69.5 (CH2); 67.6, 71.7 (Cp–CH); 70.3 (Cp–CHunsubst. ring);
78.0 (CCp); 95.1 (CCp*); 115.8, 122.9, 134.7, 134.9 (CHAr); 122.4
(Cpyr); 122.7, 152.0 (CHpyr); 153.1, 165.9 (CAr); 166.0 (CHimine).
Elemental analysis for C296H344F48Fe8N22O8P8Ru8·14DCM
(7956.9148): Found C, 46.13; H, 4.99; N, 3.55%; calcd C, 46.79;
H, 4.71; N, 3.87%. MS (HR-ESI-TOF, m/z): 400.1145 [M + 6H]14+
(where M = [8][PF6]8 − 8PF6).
General synthesis of mononuclear cationic complexes
([9][PF6]–[12][PF6]). [9][PF6]–[12][PF6] were obtained in an ana-
logous manner as [1][PF6]4–[4][PF6]8, using triethylamine
(0.043 mL, 0.309 mmol for [9][PF6]; 0.047 mL, 0.336 mmol for
[10][PF6]; 0.040 mL, 0.290 mmol for [11][PF6]; 0.043 mL,
0.307 mmol for [12][PF6]), L3 (0.0481 g, 0.295 mmol for
[9][PF6]; 0.0523 g, 0.320 mmol for [10][PF6]; 0.0474 g,
0.290 mmol for [11][PF6]; 0.0501 g, 0.307 mmol for [12][PF6]),
[(η6-p-cymene)RuCl2]2 (0.0902 g, 0.147 mmol for [9][PF6]) or
[(η6-HMB)RuCl2]2 (0.108 g, 0.160 mmol for [10][PF6]) or [(η5-
C5Me5)IrCl2]2 (0.113 g, 0.142 mmol for [11][PF6]) or [(η5-C5Me5)
RhCl2]2 (0.0926 g, 0.149 mmol for [12][PF6]), 4-ferrocenylpyri-
dine (0.0814 g, 0.309 mmol for [9][PF6]; 0.0885 g, 0.0336 mmol
for [10][PF6]; 0.0764 g, 0.290 mmol for [11][PF6]; 0.0808 g,
0.307 mmol for [12][PF6]) and NH4PF6 (0.0504 g, 0.309 mmol
for [9][PF6]; 0.0548 g, 0.336 mmol for [10][PF6]; 0.0473 g,
0.290 mmol for [11][PF6]; 0.0501 g, 0.307 mmol for [12][PF6]).
[CH3CH2CH2-(η
6-p-cymene)Ru(C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine][PF6] ([9][PF6]). Red solid. Yield: 0.2152 g, 91%. IR (ATR):
ν (cm−1) = 1609 (s & br, imine & pyridine, CvN). 1H NMR
((CD3)2CO): δ (ppm) = 1.09 (t,
3J = 7.3 Hz, 3H, NCH2CH2CH3),
1.31 & 1.23 (d, 3J = 6.9 Hz, 6H, CH(CH3)2 p-cymene), 1.82–1.91 &
2.03–2.11 (m, 2H, NCH2CH2CH3), 2.80 (s, 3H, CH3 p-cymene),
2.83–2.90 (m, 1H, CH(CH3)2 p-cymene), 3.97 (s, 5H, Cp–CHunsubst. ring),
4.43–4.49 & 4.53–4.59 (m, 2H, NCH2CH2CH3), 4.58 (t,
3J = 1.9
Hz, 2H, Cp–CH), 4.97 (t, 3J = 1.9 Hz, 2H, Cp–CH), 5.70–5.81
(m, 2H, Arp-cymene), 5.98–6.10 (m, 2H, Arp-cymene), 6.40 (ddd,
3J =
7.9, 8.9, 1.1 Hz, 1H, Ar), 6.94 (d, 3J = 8.4 Hz, 1H, Ar), 7.01 (dd,
3J = 7.9, 1.8 Hz, 1H, Ar), 7.22 (ddd, 3J = 8.5, 6.9, 1.8 Hz, 1H, Ar),
7.57 (d, 3J = 6.8 Hz, 2H, Pyr), 8.12 (s, 1H, CHimine), 8.53 (d,
3J =
6.8 Hz, 2H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm) = 10.6
(CH3); 8.1, 21.4, 22.0 (CH3 p-cymene); 25.0, 66.8 (CH2); 67.5, 71.6
(Cp–CH); 70.2 (Cp–CHunsubst. ring); 77.9 (CCp); 30.8, 83.1, 84.2,
84.5, 89.2 (CHp-cymene); 99.9, 119.9 (Cp-cymene); 114.9, 121.3,
134.8, 135.0 (CHAr); 120.3 (Cpyr); 121.6, 152.5 (CHpyr); 149.6,
164.8 (CAr); 165.9 (CHimine). Elemental analysis for C35H39F6Fe-
N2OPRu (805.5831): Found C, 52.01; H, 4.81; N, 3.37%; calcd
C, 52.18; H, 4.88; N, 3.48%. MS (HR-ESI-TOF, m/z): 398.1064
[M − (4-FcPyr)]+ (where M = [9][PF6] − PF6).
[CH3CH2CH2-(η
6-HMB)Ru(C7H5NO)-κ
2-N,O)-4-ferrocenylpyridine]
[PF6] ([10][PF6]). Red solid. Yield: 0.0330 g, 13%. IR (ATR):
ν (cm−1) = 1611 (s & br, imine & pyridine, CvN). 1H NMR
((CD3)2CO): δ (ppm) = 0.93 (t,
3J = 7.3 Hz, 3H, NCH2CH2CH3),
1.18–1.25 & 1.51–1.58 (m, 2H, NCH2CH2CH3), 2.04 (s, 18H,
CH3 HMB), 3.98–4.05 & 4.32–4.39 (m, 2H, NCH2CH2CH3), 4.07
(s, 5H, Cp–CHunsubst. ring), 4.63 (s, 2H, Cp–CH), 5.03 (d,
3J = 9.2
Hz, 2H, Cp–CH), 6.59 (t, 3J = 7.8 Hz, 1H, Ar), 7.10 (d, 3J = 8.4
Hz, 1H, Ar), 7.22 (d, 3J = 9.4 Hz, 1H, Ar), 7.28–7.34 (m, 1H, Ar),
7.76 (d, 3J = 6.6 Hz, 2H, Pyr), 8.15 (s, 1H, CHimine), 8.61 (d,
3J =
6.5 Hz, 2H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm) = 10.3
(CH3); 14.7 (CH3HMB); 25.3, 65.4 (CH2); 67.5, 71.6 (Cp–CH);
70.2 (Cp–CHunsubst. ring); 78.3 (CCp); 94.3 (CHMB); 115.4, 123.3,
134.4, 134.6 (CHAr); 121.9 (Cpyr); 122.1, 151.4 (CHpyr); 153.0,
164.9 (CAr); 165.8 (CHimine). Elemental analysis for C36H43F6Fe-
N2OPRu (821.6257): Found C, 52.51; H, 5.21; N, 3.37%; calcd
C, 52.63; H, 5.27; N, 3.41%. MS (HR-ESI-TOF, m/z): 426.1373
[M − (4-FcPyr)]+ (where M = [10][PF6] − PF6).
[CH3CH2CH2-(η
5-C5Me5)Ir(C7H5NO)-κ
2-N,O)-4-ferrocenylpyridine]
[PF6] ([11][PF6]). Red-orange solid. Yield: 0.0682 g, 55%.
IR (ATR): ν (cm−1) = 1612 (s & br, imine & pyridine, CvN). 1H
NMR ((CD3)2CO): δ (ppm) = 0.89 (t,
3J = 7.3 Hz, 3H,
NCH2CH2CH3), 1.49–1.60 (m, 2H, NCH2CH2CH3), 1.61 (s, 15H,
CH3 Cp*), 4.07 (s, 5H, Cp–CHunsubst. ring), 4.21–4.29 (m, 2H,
NCH2CH2CH3), 4.64 (t,
3J = 1.9 Hz, 2H, Cp–CH), 5.04 (d, 3J =
1.9 Hz, 2H, Cp–CH), 6.61 (t, 3J = 7.0 Hz, 1H, Ar), 7.03 (d, 3J =
8.4 Hz, 1H, Ar), 7.31 (dd, 3J = 7.7, 1.7 Hz, 1H, Ar), 7.43 (ddd,
3J = 8.6, 7.1, 1.6 Hz, 1H, Ar), 7.77 (d, 3J = 6.5 Hz, 2H, Pyr), 8.24
(s, 1H, CHimine), 8.72 (d,
3J = 6.8 Hz, 2H, Pyr). 13C{1H} NMR
((CD3)2CO): δ (ppm) = 7.73 (CH3 Cp*); 10.4 (CH3); 24.6, 67.6
(CH2); 67.7, 71.8 (Cp–CH); 70.3 (Cp–CHunsubst. ring); 78.1 (CCp);
87.2 (CCp*); 116.4, 122.5, 134.3, 135.0 (CHAr); 122.5 (Cpyr);
122.1, 150.3 (CHpyr); 150.5, 163.9 (CAr); 163.6 (CHimine).
Elemental analysis for C34H40F6FeIrN2OP (885.7300): Found C,
45.98; H, 4.74; N, 3.37%; calcd C, 46.11; H, 4.55; N, 3.16%. MS
(HR-ESI-TOF, m/z): 490.1714 [M − (4-FcPyr)]+ (where M =
[11][PF6] − PF6).
[CH3CH2CH2-(η
5-C5Me5)Rh(C7H5NO)-κ
2-N,O)-4-ferrocenylpyri-
dine][PF6] ([12][PF6]). Red solid. Yield: 0.0582 g, 49%. IR (ATR):
ν (cm−1) = 1610 (s & br, imine & pyridine, CvN). 1H NMR
((CD3)2CO): δ (ppm) = 0.88 (t,
3J = 7.4 Hz, 3H, NCH2CH2CH3),
1.37–1.41 (m, 2H, NCH2CH2CH3), 1.64 (s, 15H, CH3 Cp*), 4.08
(s, 5H, Cp–CHunsubst. ring), 4.10–4.15 (m, 2H, NCH2CH2CH3),
4.63 (t, 3J = 1.9 Hz, 2H, Cp–CH), 5.04 (d, 3J = 1.9 Hz, 2H,
Cp–CH), 6.59–6.63 (m, 1H, Ar), 7.08 (d, 3J = 8.4 Hz, 1H, Ar),
7.29 (dd, 3J = 7.8, 1.8 Hz, 1H, Ar), 7.36 (dd, 3J = 8.5, 6.9, 1.7 Hz,
1H, Ar), 7.80 (d, 3J = 6.6 Hz, 2H, Pyr), 8.23 (s, 1H, CHimine),
8.67 (d, 3J = 6.5 Hz, 2H, Pyr). 13C{1H} NMR ((CD3)2CO): δ (ppm)
= 7.68 (CH3 Cp*); 10.4 (CH3); 24.5, 65.0 (CH2); 67.6, 71.6
(Cp–CH); 70.2 (Cp–CHunsubst. ring); 75.3 (CCp); 95.1 (CCp*);
115.3, 123.2, 134.8, 135.0 (CHAr); 122.7 (Cpyr); 122.4, 150.5
(CHpyr); 152.0, 165.5 (CAr); 166.2 (CHimine). Elemental analysis
for C34H40F6FeN2OPRh (693.5100): Found C, 59.08; H, 5.74; N,
4.37%; calcd C, 58.89; H, 5.81; N, 4.04%. MS (HR-ESI-TOF,
m/z): 400.1151 [M − (4-FcPyr)]+ (where M = [12][PF6] − PF6).
Cytotoxicity studies
The human A2780 and A2780cisR ovarian carcinoma cell lines
were obtained from the European Collection of Cell Cultures
(Salisbury, UK). Non-tumorigenic HEK-293 cells were obtained
from ATCC (Sigma, Switzerland). Cells were grown routinely in
RPMI-1640 GlutaMax medium with 10% fetal bovine serum
(FBS, Pan Biotech, Germany) and 1% antibiotics at 37 °C and
5% CO2. Cytotoxicity was determined using the MTT assay
(MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide) as previously described.83 Briefly, cells were
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seeded in 96-well plates as monolayers with 100 μL of cell solu-
tion (approximately 10 000 cells) per well and pre-incubated
for 24 h in medium supplemented with 10% FBS. Compounds
were prepared as DMSO solution, then dissolved in the culture
medium and immediately serially diluted to the appropriate
concentration, to give a final DMSO concentration of 0.5%. A
100 μL portion of drug solution was added to each well and
the plates were incubated for another 72 h. Subsequently, MTT
(5 mg mL−1 solution in PBS) was added to the cells and the
plates were incubated for a further 4 h. The culture medium
was aspirated, and the purple formazan crystals formed by the
mitochondrial dehydrogenase activity of vital cells were dis-
solved in DMSO. The optical density, directly proportional to
the number of surviving cells, was quantified at 590 nm using
a multiwell plate reader and the fraction of surviving cells was
calculated from the absorbance of untreated control cells. The
IC50 values were determined by fitting the plot of the log of the
ratio between the percentages of surviving cells, divided by the
amount of dead cells, against the log of drug concentration
using a linear threshold function. Evaluation is based on
means from at least two independent experiments, each com-
prising four microcultures per concentration level.
NMR studies
For the stability/aquation studies, second generation metallo-
dendrimer [4][PF6]8 and its closest binuclear analogue
[10][PF6] was dissolved in DMSO-d6 and D2O (50 : 50% v/v,
because of limited solubility), warmed at 37 °C (to mimic
physiological temperature) before samples were monitored
using 1H and 31P{1H} NMR experiments at 37 °C over 24 hours
on a Bruker Biospin GmbH spectrometer (1H: 400.22 MHz, 31P
{1H}: 162.00 MHz).
UV-Vis studies
Absorption studies of a 0.23 mM and 0.15 mM solution of
[4][PF6]8 and [10][PF6] respectively in H2O with 0.22 mM
HEPES buﬀer, pH 6.3 were performed in the range
225–345 nm. Solutions of Red Salmon testes DNA sodium salt
were prepared fresh before each experiment using milli-Q
water. 50 μL aliquots of 50 nM DNA stock solution were added
to [4][PF6]8 and [10][PF6] to make the DNA concentrations:
2.38, 4.55, 6.52, 8.33, 10.0, 11.5, 13.0 and 14.3 nM (for [4][PF6]8
& [10][PF6]) and a further 15.5 and 16.7 nM (for [10][PF6]).
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